
Satoshi Takahashi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2910404/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood, 2004, 104, 3813-3820.	0.6	310
2	Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood, 2007, 109, 1322-1330.	0.6	271
3	Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood, 2009, 113, 1631-1638.	0.6	210
4	The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. , 2000, 64, 32-38.		132
5	Comparison of Outcomes of 8/8 and 7/8 Allele–Matched Unrelated Bone Marrow Transplantation and Single-Unit CordÂBlood Transplantation in Adults with Acute Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 330-338.	2.0	100
6	Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 1749-1758.	2.0	80
7	Different effects of HLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia. Haematologica, 2013, 98, 814-822.	1.7	77
8	The multifaceted role of plasminogen in inflammation. Cellular Signalling, 2020, 75, 109761.	1.7	68
9	Comparison of Unrelated Cord Blood Transplantation and HLA-Mismatched Unrelated Bone Marrow Transplantation for Adults with Leukemia. Biology of Blood and Marrow Transplantation, 2012, 18, 780-787.	2.0	67
10	A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy. Stem Cell Reports, 2015, 5, 597-608.	2.3	61
11	Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. International Journal of Hematology, 2011, 93, 375-382.	0.7	57
12	Central Nervous System Relapse of Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 1100-1107.	2.0	56
13	Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1702-1709.	2.0	56
14	Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma. Cancer Immunology Research, 2019, 7, 1148-1161.	1.6	56
15	Cryopreserved CD34 + Cell Dose, but Not Total Nucleated Cell Dose, Influences Hematopoietic Recovery and Extensive Chronic Graft-versus-Host Disease after Single-Unit Cord Blood Transplantation in Adult Patients. Biology of Blood and Marrow Transplantation, 2017, 23, 1142-1150.	2.0	52
16	Granulocyte colony-stimulating factor-associated aortitis in the Japanese Adverse Drug Event Report database. Cytokine, 2019, 119, 47-51.	1.4	51
17	Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy. Blood, 2015, 126, 415-422.	0.6	49
18	Genetic and epigenetic stability of oligodendrogliomas at recurrence. Acta Neuropathologica Communications, 2017, 5, 18.	2.4	47

#	Article	IF	CITATIONS
19	Impact of the Direction of HLA Mismatch on Transplantation Outcomes in Single Unrelated Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 247-254.	2.0	46
20	Varicella-zoster virus infection in adult patients after unrelated cord blood transplantation: a single institute experience in Japan. British Journal of Haematology, 2003, 122, 802-805.	1.2	43
21	Distinct molecular profile of diffuse cerebellar gliomas. Acta Neuropathologica, 2017, 134, 941-956.	3.9	40
22	Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience. Bone Marrow Transplantation, 2019, 54, 1789-1798.	1.3	39
23	Improvement of early mortality in singleâ€unit cord blood transplantation for Japanese adults from 1998 to 2017. American Journal of Hematology, 2020, 95, 343-353.	2.0	39
24	Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 2194-2200.	2.0	38
25	Single-Unit Cord Blood Transplantation after Granulocyte Colony-Stimulating Factor–Combined Myeloablative Conditioning for Myeloid Malignancies Not in Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 396-401.	2.0	37
26	Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study. Leukemia, 2020, 34, 128-137.	3.3	36
27	Does the Hematopoietic Cell Transplantation Specific Comorbidity Index (HCT-CI) Predict Transplantation Outcomes? A Prospective Multicenter Validation Study of the Kanto Study Group for Cell Therapy. Biology of Blood and Marrow Transplantation, 2014, 20, 1553-1559.	2.0	35
28	Reconstitution of Circulating Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation: Its Association with the Riboflavin Synthetic Pathway of Gut Microbiota in Cord Blood Transplant Recipients. Journal of Immunology, 2020, 204, 1462-1473.	0.4	35
29	Impact of HLA Allele Mismatch at HLA-A, -B, -C, and -DRB1 in Single Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 519-528.	2.0	34
30	Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosomeâ€positive acute lymphoblastic leukemia. Cancer Science, 2019, 110, 3255-3266.	1.7	32
31	DNA demethylation is associated with malignant progression of lower-grade gliomas. Scientific Reports, 2019, 9, 1903.	1.6	31
32	Cytokine Profiles of Pre-Engraftment Syndrome after Single-Unit Cord Blood Transplantation for Adult Patients. Biology of Blood and Marrow Transplantation, 2017, 23, 1932-1938.	2.0	29
33	Granulocyte colony-stimulating factor combined regimen in cord blood transplantation for acute myeloid leukemia: a nationwide retrospective analysis in Japan. Haematologica, 2014, 99, e264-e268.	1.7	25
34	Which is more important for the selection of cord blood units for haematopoietic cell transplantation: the number of <scp>CD</scp> 34â€positive cells or total nucleated cells?. British Journal of Haematology, 2019, 185, 166-169.	1.2	25
35	Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation. British Journal of Haematology, 1999, 104, 569-573.	1.2	23
36	Resolved versus Active Chronic Graft-versus-Host Disease: Impact on Post-Transplantation Quality of Life. Biology of Blood and Marrow Transplantation, 2019, 25, 1851-1858.	2.0	23

#	Article	IF	CITATIONS
37	Serum C-reactive protein levels affect the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients. Leukemia and Lymphoma, 2017, 58, 2731-2733.	0.6	22
38	Employment status was highly associated with quality of life after allogeneic hematopoietic cell transplantation, and the association may differ according to patient age and graft-versus-host disease status: analysis of a nationwide QOL survey. Bone Marrow Transplantation, 2019, 54, 611-615.	1.3	21
39	Clinical outcomes of persistent colonization with multidrug-resistant Gram-negative rods in adult patients undergoing single cord blood transplantation. International Journal of Hematology, 2020, 111, 858-868.	0.7	20
40	A Novel Topical Fluorescent Probe for Detection of Glioblastoma. Clinical Cancer Research, 2021, 27, 3936-3947.	3.2	20
41	Donor Leukocyte Infusion for Japanese Patients with Relapsed Leukemia After Allogeneic Bone Marrow Transplantation: Indications and Dose Escalation. Therapeutic Apheresis and Dialysis, 2001, 5, 40-45.	0.4	18
42	Associations of interactions between NLRP3 SNPs and HLA mismatch with acute and extensive chronic graft-versus-host diseases. Scientific Reports, 2017, 7, 13097.	1.6	18
43	Outcomes of patients who developed subsequent solid cancer after hematopoietic cell transplantation. Blood Advances, 2018, 2, 1901-1913.	2.5	18
44	Reduced-Toxicity Myeloablative Conditioning Consisting of Fludarabine/Busulfan/Low-Dose Total Body Irradiation/Granulocyte Colony-Stimulating Factor–Combined Cytarabine in Single Cord Blood Transplantation for Elderly Patients with Nonremission Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2019, 25, 764-770.	2.0	18
45	Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study. International Journal of Hematology, 2008, 87, 195-202.	0.7	16
46	Association analysis of the NOD2 gene with susceptibility to graft-versus-host disease in a Japanese population. International Journal of Hematology, 2011, 93, 771-778.	0.7	16
47	Effect of ABO Blood Group Incompatibility on the Outcome of Single-Unit Cord Blood Transplantation after Myeloablative Conditioning. Biology of Blood and Marrow Transplantation, 2014, 20, 577-581.	2.0	16
48	Effect of Granulocyte Colony–Stimulating Factor–Combined Conditioning in Cord Blood Transplantation for Myelodysplastic Syndrome and Secondary Acute MyeloidÅLeukemia: A Retrospective Study in Japan. Biology of Blood and Marrow Transplantation, 2015, 21, 1632-1640.	2.0	16
49	Effects of HLA mismatch on cytomegalovirus reactivation in cord blood transplantation. Bone Marrow Transplantation, 2019, 54, 1004-1012.	1.3	16
50	Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia. Leukemia, 2022, 36, 1132-1138.	3.3	16
51	Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia. Blood Cancer Journal, 2022, 12, .	2.8	16
52	Recombinant human granulocyte colony-stimulating factor (G-CSF) combined conditioning regimen for allogeneic bone marrow transplantation (BMT) in standard-risk myeloid leukemia. , 1998, 57, 303-308.		14
53	Comparable Long-Term Outcome of Unrelated Cord Blood Transplantation with Related Bone Marrow or Peripheral Blood Stem Cell Transplantation in Patients Aged 45ÂYears orÂOlder with Hematologic Malignancies after Myeloablative Conditioning. Biology of Blood and Marrow Transplantation, 2014, 20. 1150-1155.	2.0	14
54	Development of Pre-Engraftment Syndrome, but Not Acute Graft-versus-Host Disease, Reduces Relapse Rate of Acute Myelogenous Leukemia after Single Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1187-1196.	2.0	14

SATOSHI ТАКАНАЅНІ

#	Article	IF	CITATIONS
55	The Multifaceted Roles of EGFL7 in Cancer and Drug Resistance. Cancers, 2021, 13, 1014.	1.7	14
56	Comparison of graft-versus-host disease-free, relapse-free survival of transplantation using matched sibling donor, matched unrelated donor or unrelated cord blood after myeloablative conditioning for adult patients with hematological malignancies. Leukemia and Lymphoma, 2016, 57, 2126-2132.	0.6	13
57	Risk factors and characteristics of falls among hospitalized adult patients with hematologic diseases. Journal of Geriatric Oncology, 2017, 8, 363-367.	0.5	13
58	Platelet Transfusion Refractoriness in Single-Unit Cord Blood Transplantation for Adults: Risk Factors and Clinical Outcomes. Biology of Blood and Marrow Transplantation, 2018, 24, 1873-1880.	2.0	13
59	The Prognostic Impact of Pretransplantation Inflammatory and Nutritional Status in Adult Patients after Myeloablative Single Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 981-988.	2.0	13
60	The EGFL7-ITGB3-KLF2 axis enhances survival of multiple myeloma in preclinical models. Blood Advances, 2020, 4, 1021-1037.	2.5	13
61	Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis. Leukemia, 2019, 33, 2610-2618.	3.3	12
62	A cross-sectional study on late taste disorders in survivors of allogeneic hematopoietic cell transplantation. Annals of Hematology, 2017, 96, 1841-1847.	0.8	11
63	Effect of Cumulative Intravenous Voriconazole Dose on Renal Function in Hematological Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	11
64	High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation. Blood Advances, 2019, 3, 397-405.	2.5	11
65	Effects of Haplotype Matching on Outcomes after Adult Single-Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 509-518.	2.0	11
66	Impact of Homozygous Conserved Extended HLA Haplotype on Single Cord Blood Transplantation: Lessons for Induced Pluripotent Stem Cell Banking and Transplantation in Allogeneic Settings. Biology of Blood and Marrow Transplantation, 2020, 26, 132-138.	2.0	11
67	The effect of granulocyte colony-stimulating factor administration in healthy donors before bone marrow harvesting. British Journal of Haematology, 2000, 108, 747-753.	1.2	10
68	Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients. Annals of Hematology, 2016, 95, 1845-1851.	0.8	10
69	Refractory Graft-Versus-Host Disease–Free, Relapse-Free Survival as an Accurate and Easy-to-Calculate Endpoint to Assess the Long-Term Transplant Success. Biology of Blood and Marrow Transplantation, 2018, 24, 1521-1526.	2.0	10
70	Double-Unit Cord Blood Transplantation in Japan Blood, 2004, 104, 5166-5166.	0.6	10
71	Leukemia: cord blood for allogeneic stem cell transplantation. Current Opinion in Oncology, 2007, 19, 667-672.	1.1	9
72	Second allogeneic transplantation using unrelated cord blood for relapsed hematological malignancies after allogeneic transplantation. Leukemia and Lymphoma, 2016, 57, 103-109.	0.6	9

#	Article	IF	CITATIONS
73	Circulating monocyte subsets in human chronic graft-versus-host disease. Bone Marrow Transplantation, 2018, 53, 1532-1540.	1.3	9
74	Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2018, 59, 1332-1337.	0.6	9
75	Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell Transplantation. Blood Cancer Journal, 2019, 9, 31.	2.8	9
76	Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients. Bone Marrow Transplantation, 2021, 56, 2510-2517.	1.3	9
77	Second Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for Relapse of Hematological Malignancies after First Allo-HSCT. Blood, 2014, 124, 3947-3947.	0.6	9
78	Posttransplantation Engraftment and Safety of Cord Blood Transplantation with Grafts Containing Relatively Low Cell Doses in Adults. International Journal of Hematology, 2006, 84, 359-362.	0.7	8
79	Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Annals of Hematology, 2018, 97, 2173-2183.	0.8	8
80	Early fluid overload predicts higher non-relapse and overall mortality in adults after single-unit cord blood transplantation. Bone Marrow Transplantation, 2019, 54, 2096-2101.	1.3	8
81	Efficacy and safety of oral deferasirox treatment for transfusional iron overload in pure red cell aplasia patients after allogeneic stem cell transplantation. Annals of Hematology, 2019, 98, 1781-1783.	0.8	8
82	Upfront allogeneic hematopoietic cell transplantation (HCT) versus remission induction chemotherapy followed by allogeneic HCT for acute myeloid leukemia with multilineage dysplasia: A propensity score matched analysis. American Journal of Hematology, 2019, 94, 103-110.	2.0	8
83	Favorable Effect of Cytomegalovirus Reactivation on Outcomes in Cord Blood Transplant and Its Differences Among Disease Risk or Type. Biology of Blood and Marrow Transplantation, 2020, 26, 1363-1370.	2.0	8
84	The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. Bone Marrow Transplantation, 2022, 57, 57-64.	1.3	8
85	Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model. Experimental Hematology, 2015, 43, 79-88.e4.	0.2	7
86	Breakthrough fungemia due to <i><scp>C</scp>andida fermentati</i> with fks1p mutation under micafungin treatment in a cord blood transplant recipient. Transplant Infectious Disease, 2017, 19, e12634.	0.7	7
87	Efficacy and Safety of Low-Dose Liposomal Amphotericin B in Adult Patients Undergoing Unrelated Cord Blood Transplantation. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	7
88	Spray Fluorescent Probes for Fluorescence-Guided Neurosurgery. Frontiers in Oncology, 2019, 9, 727.	1.3	7
89	T memory stem cells after allogeneic haematopoietic cell transplantation: unique longâ€term kinetics and influence of chronic graftâ€versusâ€host disease. British Journal of Haematology, 2019, 186, 866-878.	1.2	7
90	Mining-Guided Machine Learning Analyses Revealed the Latest Trends in Neuro-Oncology. Cancers, 2019, 11, 178.	1.7	7

#	Article	IF	CITATIONS
91	Reduced leukemia relapse through cytomegalovirus reactivation in killer cell immunoglobulin-like receptor-ligand-mismatched cord blood transplantation. Bone Marrow Transplantation, 2021, 56, 1352-1363.	1.3	7
92	Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia. International Journal of Hematology, 2021, 113, 840-850.	0.7	7
93	Low seroprevalence ofHelicobacter pylori in patients with leukemia. , 1999, 60, 253-253.		6
94	Multiple allogeneic progenitors in combination function as a unit to support early transient hematopoiesis in transplantation. Journal of Experimental Medicine, 2016, 213, 1865-1880.	4.2	6
95	The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS. Hematological Oncology, 2017, 35, 341-349.	0.8	6
96	Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8. Annals of Hematology, 2017, 96, 469-478.	0.8	6
97	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8. Biology of Blood and Marrow Transplantation, 2017, 23, 75-80.	2.0	6
98	Outcomes after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia harboring t(7;11)(p15;p15). Haematologica, 2018, 103, e69-e72.	1.7	6
99	Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free medium. Cytotherapy, 2018, 20, 1182-1190.	0.3	6
100	Clinical course of autologous recovery with chromosomal abnormalities after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 1023-1028.	1.3	6
101	Effect of Multiple HLA Locus Mismatches on Outcomes after Single Cord Blood Transplantation. Transplantation and Cellular Therapy, 2022, 28, 398.e1-398.e9.	0.6	6
102	Red blood cell transfusion burden by day 30 predicts mortality in adults after single-unit cord blood transplantation. Bone Marrow Transplantation, 2019, 54, 1836-1846.	1.3	5
103	Lower vancomycin trough levels in adults undergoing unrelated cord blood transplantation. Leukemia and Lymphoma, 2021, 62, 348-357.	0.6	5
104	Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation. Bone Marrow Transplantation, 2022, 57, 43-50.	1.3	5
105	Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades. Blood Advances, 2022, 6, 4558-4569.	2.5	5
106	Long-term outcomes of granulocyte colony-stimulating factor-combined conditioning in allogeneic hematopoietic stem cell transplantation from HLA-identical family donors for myeloid malignancies. Leukemia Research, 2015, 39, 625-631.	0.4	4
107	Early phase mixed chimerism in bone marrow does not affect long-term outcomes of myeloablative single-unit cord blood transplantation for adult patients with hematological malignancies. Leukemia and Lymphoma, 2016, 57, 2848-2854.	0.6	4
108	Impact of hematogones on the long-term outcomes of single-unit cord blood transplantation for adult patients. Leukemia and Lymphoma, 2017, 58, 118-126.	0.6	4

#	Article	IF	CITATIONS
109	Monocyte subsets and their phenotypes during treatment with BCRâ€ABL1 tyrosine kinase inhibitors for Philadelphia chromosomeâ€positive leukemia. Hematological Oncology, 2018, 36, 451-456.	0.8	4
110	Does marital status affect the outcomes after allogeneic hematopoietic cell transplantation?. Bone Marrow Transplantation, 2018, 53, 774-779.	1.3	4
111	Fungemia due to Fusarium solani under low-dose liposomal amphotericin B in a patient after cord blood transplantation. Journal of Infection and Chemotherapy, 2019, 25, 635-638.	0.8	4
112	Risk factors and survival impact of readmission after single-unit cord blood transplantation for adults. International Journal of Hematology, 2019, 109, 115-124.	0.7	4
113	Outcomes and Prognostic Factors for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A KSGCT Multicenter Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, 998-1004.	2.0	4
114	Radiationâ€free myeloablative conditioning consisting of fludarabine added to fullâ€dose busulfan and cyclophosphamide in singleâ€unit cord blood transplantation for adults. European Journal of Haematology, 2021, 107, 374-376.	1.1	4
115	Cord blood index predicts engraftment and early non-relapse mortality in adult patients with single-unit cord blood transplantation. Bone Marrow Transplantation, 2021, 56, 2771-2778.	1.3	4
116	Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies. Annals of Hematology, 2022, 101, 177-189.	0.8	4
117	The Production of Granulocyte Colony-Stimulating Factor and Interleukin 6 by Human Bone arrow Stromal Cells in Aplastic Anemia Tohoku Journal of Experimental Medicine, 1993, 169, 325-334.	0.5	3
118	TCR-Vβ repertoire analysis with RT-PCR was useful for the early detection of pulmonary relapsed T-cell lymphoma after autologous peripheral blood stem cell transplantation. , 2000, 64, 124-127.		3
119	Alloimmune hemolysis due to major RhE incompatibility after unrelated cord blood transplantation. Leukemia and Lymphoma, 2018, 59, 1000-1003.	0.6	3
120	Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplant. Bone Marrow Transplantation, 2019, 54, 2020-2026.	1.3	3
121	HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome. Haematologica, 2019, 104, 1055-1061.	1.7	3
122	Stopping tyrosine kinase inhibitors started after allogeneic HCT in patients with Philadelphia chromosome-positive leukemia. Bone Marrow Transplantation, 2021, 56, 1402-1412.	1.3	3
123	The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic venoâ€occlusive disease after stem cell transplantation. American Journal of Hematology, 2000, 64, 32-38.	2.0	3
124	Matched HLA Haplotype Contributes to Reduce Sever Acute GVHD with Conserving GVL Effect in HLA-Mismatched Cord Blood Transplantation,. Blood, 2011, 118, 4140-4140.	0.6	3
125	The Impact of Donor Age on Outcome after Unrelated Bone Marrow Transplantation: Comparison with Unrelated Cord Blood Transplantation. Blood, 2015, 126, 154-154.	0.6	3
126	High Prevalence of Left Ventricular Non-Compaction and Its Effect on Chemotherapy-Related Cardiac Dysfunction in Patients With Hematological Diseases. Circulation Journal, 2020, 84, 1957-1964.	0.7	3

#	Article	IF	CITATIONS
127	Remission of remitting seronegative symmetrical synovitis with pitting edema after unrelated cord blood transplantation for myelodysplastic syndrome. Annals of Hematology, 2016, 95, 523-524.	0.8	2
128	Allogeneic haematopoietic cell transplantation for adult acute myeloid leukaemia in second remission: a retrospective study of the Adult Acute Myeloid Leukaemia Working Group of the Japan Society for Haematopoietic Cell Transplantation (<scp>JSHCT</scp>). British Journal of Haematology, 2018, 182, 245-250.	1.2	2
129	<i>Candida</i> colonization is associated with severe acute GVHD in adult patients undergoing singleâ€unit cord blood transplantation. European Journal of Haematology, 2020, 104, 74-76.	1.1	2
130	Prognostic Impact of the Fractionation of Total Body Irradiation for Patients with Acute Myeloid Leukemia Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 185.e1-185.e6.	0.6	2
131	Novel Indicators of Transplant Outcomes for PhALL: Current Molecular-Relapse-Free Survival. Transplantation and Cellular Therapy, 2021, 27, 800.e1-800.e8.	0.6	2
132	Impact of Acute GVHD on Immune Reconstitution after Cord Blood Transplantation in Adult Blood, 2004, 104, 984-984.	0.6	2
133	Clinical Outcomes of Cord Blood Transplantation from Unrelated Donors Comparable with Marrow or Blood Transplantation from Related Donors in Adults: A Single Institute Analysis Blood, 2005, 106, 306-306.	0.6	2
134	Changes In Incidence and Causes of Non-Relapse Mortality (NRM) After Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Are Transplants Improving?. Blood, 2010, 116, 901-901.	0.6	2
135	Mitochondrial Antisense RNA for Cytochrome C Oxidase (MARCO) Can Induce Morphologic Changes and Cell Death in Human Hematopoietic Cell Lines. Blood, 1997, 90, 4567-4577.	0.6	2
136	Impact of Homozygous Conserved Extended HLA Haplotypes on Cord Blood Transplantation: Implications for Induced Pluripotent Stem Cell Banking and Transplantation. Blood, 2018, 132, 2097-2097.	0.6	2
137	Disseminated Tuberculosis with Cholecystitis in a Patient after Cord Blood Transplantation. Internal Medicine, 2020, 59, 2769-2771.	0.3	2
138	HLA 1–3 antigenâ€mismatched related peripheral blood stem cells transplantation using lowâ€dose antithymocyte globulin versus unrelated cord blood transplantation. American Journal of Hematology, 2022, 97, 311-321.	2.0	2
139	Improved outcomes of single-unit cord blood transplantation for acute myeloid leukemia by killer immunoglobulin-like receptor 2DL1-ligand mismatch. Bone Marrow Transplantation, 2022, 57, 1171-1179.	1.3	2
140	siRNA against CD40 delivered via a fungal recognition receptor ameliorates murine acute graftâ€versusâ€host disease. EJHaem, 0, , .	0.4	2
141	Long-term persistent donor–recipient mixed chimerism without disease recurrence after myeloablative single-unit cord blood transplantation in adult acute myeloid leukemia following myelodysplastic syndrome. Leukemia and Lymphoma, 2017, 58, 2973-2975.	0.6	1
142	Severe infusion-related toxicity after a second unrelated cord blood transplantation. Cytotherapy, 2017, 19, 1013-1014.	0.3	1
143	Characterization of In Vitro Expanded Virus-Specific T cells for Adoptive Immunotherapy against Virus Infection. Japanese Journal of Infectious Diseases, 2018, 71, 122-128.	0.5	1
144	Different impact of BCRâ€ABL transcripts on allogeneic hematopoietic cell transplantation from different graft sources for Ph + ALL with minimal residual disease. American Journal of Hematology, 2019, 94, E301-E305.	2.0	1

#	Article	IF	CITATIONS
145	Epstein–Barr virus–associated post-transplant lymphoproliferative disorder among long-term survivors of adults after single cord blood transplantation without antithymocyte globulin. Annals of Hematology, 2019, 98, 2613-2615.	0.8	1
146	Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysis. Bone Marrow Transplantation, 2020, 55, 1497-1501.	1.3	1
147	Impact of Intestinal Microbiota on Reconstitution of Circulating Monocyte, Dendritic Cell, and Natural Killer Cell Subsets in Adults Undergoing Single-Unit Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, e292-e297.	2.0	1
148	Could the minimum number of haematopoietic stem cells to obtain engraftment exist in unrelated, single cord blood transplantation?. British Journal of Haematology, 2020, 189, e56-e60.	1.2	1
149	Early-Phase Peripheral Blood Eosinophilia Predicts Lower Overall and Non-Relapse Mortality After Single-Unit Cord Blood Transplantation. Transplantation and Cellular Therapy, 2021, 27, 336.e1-336.e9.	0.6	1
150	Analysis of Relationships between Immune Checkpoint and Methylase Gene Polymorphisms and Outcomes after Unrelated Bone Marrow Transplantation. Cancers, 2021, 13, 2752.	1.7	1
151	Hematological effects on peri-transplant use of linezolid in adults undergoing single-unit cord blood transplantation. Annals of Hematology, 2021, 100, 2867-2869.	0.8	1
152	Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis. Annals of Hematology, 2021, 100, 2763-2771.	0.8	1
153	Recombinant human granulocyte colony-stimulating factor (G-CSF) combined conditioning regimen for allogeneic bone marrow transplantation (BMT) in standard-risk myeloid leukemia. , 1998, 57, 303.		1
154	Who Is the Best Donor for the Second Transplant?: HLA Discrepancy between Graft and Host Rather Than That Graft and First Donor May Impact the Second Transplant Outcome from the JSHCT. Blood, 2018, 132, 4635-4635.	0.6	1
155	Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults Blood, 2005, 106, 1134-1134.	0.6	1
156	Patient-Reported Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Types and Severity of Chronic Gvhd. Blood, 2016, 128, 1240-1240.	0.6	1
157	Immune-Mediated Optic Neuritis After Unrelated Allogeneic Bone Marrow Transplantation. Blood, 1998, 91, 2619-2620.	0.6	1
158	Optimal time and threshold of absolute lymphocyte count recovery as a prognostic factor after singleâ€unit cord blood transplantation in adults. EJHaem, 2022, 3, 191-198.	0.4	1
159	Here comes the cord. Blood Research, 2014, 49, 209.	0.5	Ο
160	Multi-locus sequence analysis for identification of Achromobacter xylosoxidans from blood culture. Infectious Diseases, 2016, 48, 864-866.	1.4	0
161	Azacitidine effectively reduces TP53-mutant leukemic cell burden in secondary acute myeloid leukemia after cord blood transplantation. Leukemia and Lymphoma, 2018, 59, 2755-2756.	0.6	0
162	Circulating unconventional Tâ€cell subsets during treatment with BCRâ€ABL1 tyrosine kinase inhibitors for Philadelphia chromosomeâ€positive leukemia. European Journal of Haematology, 2019, 103, 623-625.	1.1	0

#	Article	IF	CITATIONS
163	Efficacy and safety of micafungin in unrelated cord blood transplant recipients. Annals of Hematology, 2019, 98, 2593-2600.	0.8	Ο
164	Tuberculous pleurisy in an adult patient after cord blood transplantation. EJHaem, 2020, 1, 424-425.	0.4	0
165	Telomere length in CD4 ⁺ and CD8 ⁺ T cells among longâ€ŧerm survivors of adults after single cord blood transplantation. European Journal of Haematology, 2020, 104, 509-511.	1.1	О
166	Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter Analysis. Transplantation and Cellular Therapy, 2021, 27, 70.e1-70.e8.	0.6	0
167	Effect of polymorphism in base excision repair genes on outcomes in adults following myeloablative single-unit cord blood transplantation. Leukemia and Lymphoma, 2021, 62, 1019-1021.	0.6	0
168	Prognostic impacts of peripheral blood erythroblasts after singleâ€unit cord blood transplantation. International Journal of Laboratory Hematology, 2021, 43, 1437-1442.	0.7	0
169	Momentum of neutrophil recovery using an exponential growth model predicts the prognosis of single cord blood transplantation. International Journal of Laboratory Hematology, 2021, 43, 1465-1471.	0.7	Ο
170	Contribution of T-Cell Reconstitution during the Early Phase after Cord Blood Transplantation to Favorable Clinical Outcomes Blood, 2004, 104, 2227-2227.	0.6	0
171	Role of Chemotherapy before Allogeneic Stem Cell Transplantation (ALLO-SCT) from an HLA-Identical Sibling Donor for Myelodysplastic Syndrome (MDS) Blood, 2004, 104, 5126-5126.	0.6	0
172	Incidence, Risk Factors and Outcomes of Bronchiolitis Obliterans after Allogeneic Stem Cell Transplantation Blood, 2006, 108, 3365-3365.	0.6	0
173	Unrelated Cord Blood Transplanation for Malignant Lymphoma: A Retrospective Study from the Japan Cord Blood Bank Network (JCBNW) Blood, 2007, 110, 2026-2026.	0.6	0
174	Flow Cytometric Analysis of Donor-Recipient Chimerism Using Anti-HLA Antibody after HLA-Mismatched Cord Blood Transplantation Blood, 2007, 110, 2008-2008.	0.6	0
175	Large Scale Selective Ex Vivo Expansion of CD4+CD25+FOXP3+ Regulatory T Cells from Peripheral Blood Blood, 2008, 112, 2344-2344.	0.6	Ο
176	Leukemogenic Fusion Gene (p190 BCR-ABL) Transduction Into Hematopoietic Stem/Progenitor Cells In the Common Marmoset. Blood, 2010, 116, 4323-4323.	0.6	0
177	A Plasmin Inhibitor Prevents Lethal Acute Graft-Versus-Host Disease in Mice. Blood, 2011, 118, 1897-1897.	0.6	0
178	Allogeneic hematopoietic stem cell transplantation for primary and secondary myelofibrosis. Journal of Hematopoietic Cell Transplantation, 2012, 1, 15-23.	0.1	0
179	Novel Therapeutic Approach To Graft-Versus-Host Disease With Allele-Specific Anti-HLA Monoclonal Antibody. Blood, 2013, 122, 4462-4462.	0.6	0
180	Proof of Benefit in Multiple-Cord Blood Transplantation Evidenced By Early Hematopoietic Reconstitution. Blood, 2015, 126, 3071-3071.	0.6	0

#	Article	IF	CITATIONS
181	VIII. Clinical Developments and Challenges of Cellular Products in Japan. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1411-1416.	0.0	Ο
182	Impact of a prior history of cancer on prognosis after myeloablative single-unit cord blood transplantation. Japanese Journal of Clinical Oncology, 2021, 51, 657-660.	0.6	0
183	Comparing Single Cord Blood Transplantation and Matched Related Donor Transplantation in Non-Remission Acute Myeloid Leukemia. Blood, 2021, 138, 1790-1790.	0.6	Ο
184	Allogeneic Stem Cell Transplantation Conditioned with Myeloablative Regimens Containing Total Body Irradiation in Adolescent and Young Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia Who Were Treated with Pediatric-Type Chemotherapy. Blood, 2021, 138, 2283-2283.	0.6	0
185	The Role of Fibrinolytic Factors, a Subset of Angiocrine Factors in Cytokine Storm-Associated Diseases. Blood, 2020, 136, 33-34.	0.6	0
186	Early prediction of neutrophil engraftment using manual leukocyte differential count after cord blood transplantation. International Journal of Laboratory Hematology, 2022, 44, .	0.7	0
187	Long-term incidence of varicella zoster virus disease in adults receiving single-unit cord blood transplantation. Transplantation and Cellular Therapy, 2022, , .	0.6	ο
188	The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, , .	0.6	0
189	Total body irradiation-based versus busulfan-based myeloablative conditioning for single-unit cord blood transplantation in adults. Leukemia and Lymphoma, 2021, , 1-11.	0.6	Ο